TL;DR: The Wegovy pill is dosed at 25 mg once daily; the Wegovy injection is dosed at 2.4 mg once weekly. Multiplied across seven days, that’s 175 mg administered orally per week against 2.4 mg injected — roughly 73 times more drug by mouth for a broadly comparable weight-loss effect. That gap isn’t potency, it’s absorption: oral semaglutide is co-formulated with an enhancer called SNAC, and even with it, only a small, variable fraction of each tablet reaches circulation. That mechanism is why the dosing rules are so strict, why food wrecks the pill, and why a missed dose means something different for each route.
Two doses that don’t look like they belong to the same drug
Semaglutide is one molecule with two very different delivery numbers attached to it. Injectable semaglutide for weight management is dosed at 2.4 mg once weekly, subcutaneously — the number most people associate with what semaglutide is. Oral semaglutide, the Wegovy pill, is dosed at 25 mg once daily — a number that, on first glance, looks like a typo.
It isn’t. The tablet comes in four strengths — 1.5 mg, 4 mg, 9 mg, and 25 mg — titrated up over about three months to the 25 mg maintenance dose, the same slow-climb logic as the weekly injectable schedule covered in our semaglutide dosing and titration guide. The destination doses just live on completely different scales.
Put those two maintenance doses side by side and the pill looks like it delivers a wildly higher amount of drug for a similar outcome. That comparison is correct — and exactly why it’s worth unpacking.
Do the math: 175 mg vs 2.4 mg
This is the single fact that makes the rest of the article make sense, so it’s worth spelling out rather than waving at.
If both routes absorbed semaglutide with similar efficiency, 25 mg daily would produce an effect wildly out of proportion to 2.4 mg weekly. It doesn’t, because almost none of that 175 mg is actually absorbed — the rest is degraded, diluted, or excreted before it can do anything.
Why the gap exists: peptides get digested
Semaglutide is a peptide — a chain of amino acids held together by bonds that digestive enzymes are built to break. Swallow a peptide unprotected and the stomach treats it like the protein in a meal: pepsin and acid dismantle it before it reaches the small intestine, and almost nothing intact survives to cross the gut wall. This is the same basic problem covered from the injectable-peptide side in our BPC-157 oral vs injectable comparison — most peptides simply are not oral drugs.
Oral semaglutide gets around this with a co-formulated excipient called SNAC (salcaprozate sodium), a small-molecule absorption enhancer packed into the same tablet. SNAC does two things mechanically:
- It locally raises gastric pH near the dissolving tablet, creating a brief pocket where pepsin — which needs acidity to work — is less effective at breaking down the peptide.
- It promotes transcellular absorption, temporarily easing semaglutide’s passage directly through gastric epithelial cells.
That combination is genuinely clever engineering, and it’s the only reason an oral GLP-1 peptide exists at all. But it’s a local, transient, imperfect fix, not a change that makes the stomach broadly hospitable to peptides. Absolute oral bioavailability of semaglutide is reported as low, generally cited in the sub-1% range, and notably variable both between individuals and from dose to dose within the same person. That variability, more than the low number itself, is why the dosing rules around the tablet are so strict — inconsistent absorption is the thing the protocol is fighting.
What the trials actually measured — and why the numbers aren’t interchangeable
The headline weight-loss figures for each route come from different trials with different designs, and conflating them is the most common mistake in casual comparisons.
STEP 1 studied injectable semaglutide 2.4 mg once weekly over 68 weeks and reported a mean weight loss of about 14.9% — the same figure referenced in our piece on GLP-1 weight-loss plateaus, where it marks the nadir most injectable users eventually reach.
OASIS 4 studied oral semaglutide 25 mg once daily over 64 weeks and reported two different numbers depending on the estimand: about 16.6% mean weight loss under full adherence to the trial protocol, and about 13.6% under the treatment-policy estimand, which counts everyone as randomized regardless of whether they stayed on the drug for the full 64 weeks (versus roughly 2.7% and 2.2% for placebo, respectively).
STEP 1 (injectable, 68 wk) vs OASIS 4 (oral, 64 wk). Different trials, different populations, different estimands — not a head-to-head.
That spread between 16.6% and 13.6% inside a single trial is itself the point: oral semaglutide’s real-world effect depends heavily on whether someone takes it correctly, every day, under the right conditions. The injectable’s once-weekly design is far more forgiving of an imperfect week. Neither figure is “the” oral number, and neither trial is a head-to-head with the other — stacking their headline percentages against each other as if they measured the same thing overstates the precision of the comparison.
Why the tablet comes with strict rules
Because absorption is already marginal and food makes it worse, the label conditions around the oral tablet exist to protect the small fraction that does get through:
- Take it first thing in the morning, on an empty stomach. Food or fluid already present dilutes the local pH effect SNAC depends on.
- Swallow it with no more than about four ounces (roughly half a glass) of plain water. More liquid dilutes the tablet’s local environment before it can work.
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medication. Introducing food or pills too soon interrupts the narrow absorption window entirely.
None of this is fussiness for its own sake — it’s damage control around a leaky delivery system. Skip the empty-stomach rule and the tablet may deliver meaningfully less semaglutide than the trials assumed.
Missing a dose means something different on each route
Injectable semaglutide has a roughly week-long half-life, so missing it by a day or two barely dents circulating drug levels — the previous week’s dose is still largely on board. Missing an oral 25 mg dose is sharper: that day’s absorption window is simply gone, stacking one more source of variability onto a route that’s already less consistent day to day. That’s a direct consequence of how differently adherence is baked into each trial’s estimand — the injectable shrugs off an occasional miss; the tablet is far less forgiving of one.
Oral vs injectable semaglutide: side by side
| Factor | Oral (Wegovy pill) | Injectable (Wegovy pen) |
|---|---|---|
| Dose | 25 mg maintenance | 2.4 mg maintenance |
| Frequency | Once daily | Once weekly |
| Weekly total administered | 175 mg | 2.4 mg |
| Absolute bioavailability | Low, sub-1% range, variable | Effectively complete (injected) |
| Tablet/pen strengths | 1.5, 4, 9, 25 mg | 0.25, 0.5, 1, 1.7, 2.4 mg |
| Reported weight loss | ~16.6% (adherent) / ~13.6% (treatment-policy), OASIS 4 | ~14.9%, STEP 1 |
| Administration conditions | Empty stomach, minimal water, 30-min wait | No fasting requirement |
| Missed-dose impact | Meaningful — that day’s window is lost | Small — half-life buffers a short gap |
| Adherence sensitivity | High — drives the estimand gap above | Lower |
This table describes trade-offs, not a winner. Absorption reliability and dosing convenience pull in opposite directions, and which matters more depends on which failure mode is more likely: forgetting a weekly pen, or forgetting the empty-stomach ritual on a given morning.
Which route actually fits a given routine
Neither route is “better” in the abstract — each trades one kind of certainty for another. Injectable semaglutide asks for one correctly timed event per week and then largely takes adherence out of the picture. Oral semaglutide asks for a small, precise ritual every morning — fasting, minimal water, a 30-minute wait — in exchange for never handling a needle. For more on where the pill fits in the wider landscape, see our dedicated oral semaglutide (Wegovy pill) guide.
The 73x arithmetic isn’t a mark against the tablet. It’s what it costs, in raw drug, to get a comparable amount of intact semaglutide across a leaky gastric barrier instead of straight into the bloodstream. Framed that way, the pill’s dosing quirks stop looking arbitrary and start looking like exactly what they are: engineering choices built around a hard absorption ceiling.
Frequently asked questions
Why is oral semaglutide dosed so much higher than injectable semaglutide?
Because most of an oral dose never reaches circulation. Semaglutide is a peptide, and swallowed peptides are broken down by stomach acid and enzymes before they can be absorbed. The tablet is co-formulated with SNAC to protect a small fraction of the dose long enough to cross the stomach lining, but absolute bioavailability stays low and variable, so the dose is scaled up to compensate.
Is 25 mg of oral semaglutide the same as 2.4 mg injected?
No, and they shouldn’t be treated as interchangeable numbers. 25 mg once daily works out to 175 mg administered per week, versus 2.4 mg injected once weekly — roughly 73 times more drug by mouth. The two routes land in a broadly similar weight-loss range in their respective trials, but that similarity comes from very different absorbed amounts, not equal dosing.
Why do I have to take the oral semaglutide tablet on an empty stomach?
Because the SNAC absorption enhancer in the tablet works best in a narrow, transient window right after swallowing. Food or fluid already in the stomach dilutes the local pH shift SNAC creates and crowds the absorption surface, which is why the tablet is meant to be taken first thing in the morning with minimal water and at least 30 minutes before anything else.
Does missing one oral dose matter more than missing one injection?
Yes, in relative terms. Injectable semaglutide has a roughly week-long half-life, so a day or two of delay barely changes circulating levels. A missed oral tablet loses that day’s entire absorption window outright, adding to variability that the injectable route mostly avoids.
Are the weight-loss percentages for oral and injectable semaglutide directly comparable?
Not directly. STEP 1 (injectable, 68 weeks) reported about 14.9% mean loss. OASIS 4 (oral, 64 weeks) reported about 16.6% under full adherence and about 13.6% under the treatment-policy estimand, which counts people who didn’t stay on the drug the whole time. Different trials and populations — useful context, not a head-to-head result.
What are the available strengths for oral semaglutide tablets?
The oral semaglutide (Wegovy pill) tablets come in four strengths — 1.5 mg, 4 mg, 9 mg, and 25 mg. Dosing starts at the lowest strength and steps up over roughly three months to the 25 mg maintenance dose, similar in spirit to the weekly step-up used with the injectable pen.